Adaptive RadioTherapy for OroPharynx Cancer (NCT04901234)
Adaptive RadioTherapy for Locally Advanced OroPharynx Cancer (ART-OPC) A Phase II Randomized Trial
🩺 Plain-English Summary (8th-Grade Level)
This is a phase II randomized trial, where patients with histologically proven squamous cell carcinoma of oropharynx that have primary tumor (T3 - T4) in place, treated with curative intent chemoradiation, will be randomized to systematic mid-treatment MRI-based radiotherapy adaptation vs. standard of care. The primary objective is to compare patient-rated dysphagia (as assessed by the MD Anderson Dysphagia Inventory composite score at 6 months post-treatment in patients undergoing routine mid-treatment MR-guided radiotherapy adaptation vs. in patients receiving the current standard of care.
Who can join: Review the eligibility criteria below.
Location: Austin Health — Melbourne
Age range: 18 Years
🧪 Interventions in This Study
- Standard radiotherapy +/- chemotherapy (RADIATION)
- Experimental radiotherapy +/- chemotherapy (RADIATION)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- Austin Health — Melbourne,
- Centre Hospitalier de l'Université de Montréal — Montreal, Quebec
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Oropharynx Cancer
- Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer) — La Jolla, California
- Radiotherapy Dose De-escalation in HPV-Associated Cancers of the Oropharynx — Durham, North Carolina
- Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer — Ann Arbor, Michigan
- Dose Adjusted Chemoradiotherapy in HPV-Associated Oropharynx Cancer of the Elderly — Jacksonville, Florida
- Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer — Philadelphia, Pennsylvania
- Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer — Pittsburgh, Pennsylvania
Explore by condition: All Oropharynx Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.